JP2015509963A - Ｔｌｒ４アゴニストを含む混合ワクチン - Google Patents

Ｔｌｒ４アゴニストを含む混合ワクチン Download PDF

Info

Publication number
JP2015509963A
JP2015509963A JP2014560384A JP2014560384A JP2015509963A JP 2015509963 A JP2015509963 A JP 2015509963A JP 2014560384 A JP2014560384 A JP 2014560384A JP 2014560384 A JP2014560384 A JP 2014560384A JP 2015509963 A JP2015509963 A JP 2015509963A
Authority
JP
Japan
Prior art keywords
toxoid
composition
antigen
composition according
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014560384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509963A5 (enExample
Inventor
シモーネ ブファーリ，
シモーネ ブファーリ，
バールバラ バウドナー，
バールバラ バウドナー，
デレク オーヘイガン，
デレク オーヘイガン，
シン，　マンモハン
マンモハン シン，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015509963A publication Critical patent/JP2015509963A/ja
Publication of JP2015509963A5 publication Critical patent/JP2015509963A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014560384A 2012-03-08 2013-03-08 Ｔｌｒ４アゴニストを含む混合ワクチン Pending JP2015509963A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261608409P 2012-03-08 2012-03-08
US61/608,409 2012-03-08
US201261697745P 2012-09-06 2012-09-06
US61/697,745 2012-09-06
PCT/EP2013/054674 WO2013132043A1 (en) 2012-03-08 2013-03-08 Combination vaccines with tlr4 agonists

Publications (2)

Publication Number Publication Date
JP2015509963A true JP2015509963A (ja) 2015-04-02
JP2015509963A5 JP2015509963A5 (enExample) 2016-04-28

Family

ID=47844315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560384A Pending JP2015509963A (ja) 2012-03-08 2013-03-08 Ｔｌｒ４アゴニストを含む混合ワクチン

Country Status (5)

Country Link
US (1) US20150125486A1 (enExample)
EP (1) EP2822584A1 (enExample)
JP (1) JP2015509963A (enExample)
CN (1) CN104159603A (enExample)
WO (1) WO2013132043A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502075A (ja) * 2017-11-03 2021-01-28 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカウイルスを不活化するため、及び不活化の完全性を決定するための方法
JP2022511511A (ja) * 2018-12-05 2022-01-31 サノフィ パスツール インコーポレイテッド 百日咳ブースターワクチン
JP2022534038A (ja) * 2019-05-23 2022-07-27 ザ ユニバーシティー オブ モンタナ Ｔｌｒ受容体リガンドをベースとするワクチンアジュバント
JP2023134630A (ja) * 2017-11-30 2023-09-27 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
JP2014525429A (ja) * 2011-09-01 2014-09-29 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
EP3752182B1 (en) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like receptor ligands

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508849A (ja) * 2001-04-03 2005-04-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FI945483A7 (fi) * 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69331495T2 (de) 1992-08-31 2002-10-31 Baxter Healthcare S.A., Wallisellen Impfstoffe gegen neisseria meningitidis gruppe c
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
BR9608612A (pt) 1995-06-07 1999-05-04 Smithkline Beecham Biolog Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DK1233784T3 (da) 1999-12-02 2008-09-01 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
EP2957300B1 (en) 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2851088A1 (en) 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012B (zh) 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖－蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5049264B2 (ja) 2005-04-08 2012-10-17 ワイス・エルエルシー ｐＨ操作によるストレプトコッカス・ニューモニエ多糖からの混入物の分離
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR056591A1 (es) 2005-10-28 2007-10-10 Vaxinnate Corp Polipeptidos ligandos para receptor 4 simil toll (tlr4)
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
KR101467002B1 (ko) 2006-10-10 2014-12-01 와이어쓰 엘엘씨 스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
TR201811280T4 (tr) * 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508849A (ja) * 2001-04-03 2005-04-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502075A (ja) * 2017-11-03 2021-01-28 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカウイルスを不活化するため、及び不活化の完全性を決定するための方法
JP7443232B2 (ja) 2017-11-03 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活化するため、及び不活化の完全性を決定するための方法
JP2023134630A (ja) * 2017-11-30 2023-09-27 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
JP2022511511A (ja) * 2018-12-05 2022-01-31 サノフィ パスツール インコーポレイテッド 百日咳ブースターワクチン
JP7605739B2 (ja) 2018-12-05 2024-12-24 サノフィ パスツール インコーポレイテッド 百日咳ブースターワクチン
JP2022534038A (ja) * 2019-05-23 2022-07-27 ザ ユニバーシティー オブ モンタナ Ｔｌｒ受容体リガンドをベースとするワクチンアジュバント
JP7682544B2 (ja) 2019-05-23 2025-05-26 ザ ユニバーシティー オブ モンタナ Ｔｌｒ受容体リガンドをベースとするワクチンアジュバント

Also Published As

Publication number Publication date
EP2822584A1 (en) 2015-01-14
WO2013132043A1 (en) 2013-09-12
US20150125486A1 (en) 2015-05-07
CN104159603A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
US10603369B2 (en) Combination vaccines with lower doses of antigen and/or adjuvant
AU2014204425B2 (en) Formulation of meningitis vaccines
JP5135220B2 (ja) 血清群ｃ髄膜炎菌を含む複数ワクチン接種
CA2646993C (en) Regimens for immunisation with meningococcal conjugates
JP6324961B2 (ja) 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
JP2010529103A5 (enExample)
CA2746579C (en) Mixing lyophilised meningococcal vaccines with d-t-pa vaccines
JP2015509963A (ja) Ｔｌｒ４アゴニストを含む混合ワクチン
WO2014095771A1 (en) Conjugates for protecting against diphtheria and/or tetanus
AU2013222031A1 (en) Regimens for immunisation with meningococcal conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170622